Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 7/20 | 0.71 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.71 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | CPT1A | P50416 | 2/20 | 0.51 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4456291 | 0.92 | PTGER4 (0.69) | PTGER4PTGER2XDHAURKACPT1A | |
| SCHEMBL4450402 | 0.86 | PTGER4 (0.68) | PTGER4PTGER2XDHCPT1ACPT1B | |
| SCHEMBL4448217 | 0.83 | PTGER4 (1.00) | PTGER4PTGER2 | |
| SCHEMBL4447261 | 0.82 | PTGER4 (0.82) | PTGER4PTGER2 | |
| SCHEMBL4450530 | 0.82 | PTGER4 (0.66) | PTGER4PTGER2XDHCPT1ACPT1B | |
| SCHEMBL4447268 | 0.80 | PTGER4 (0.75) | PTGER4PTGER2CXCR3 | |
| SCHEMBL5359681 | 0.79 | PTGER4 (0.74) | PTGER4PTGER2MAPTTHRB | |
| SCHEMBL5364975 | 0.77 | PTGER4 (0.63) | PTGER4PTGER2MAPTTHRB | |
| SCHEMBL4450910 | 0.77 | EPHX2 (0.52) | PTGER4XDHCPT1ACPT1BEPHX2 | |
| SCHEMBL5354862 | 0.77 | PTGER4 (0.70) | PTGER4PTGER2MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1867551-B | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | RAQUALIA PHARMA INC | 2013-09-11 | — | — | CN | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| CN-1867551-A | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | PFIZER (US) | 2006-11-22 | — | — | CN | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | PTGER4 13/4885PTGER2 11/4885XDH 877/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | PTGER4 1/4885PTGER2 2/4885XDH 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.